Genespire is a biotechnology company focused on the development of transformative gene therapies for patients affected by genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases.

Sangamo Therapeutics is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies.

Merck (d.b.a. EMD Millipore in the U.S. and Canada) is a German chemical and pharmaceutical company. Merck, also known as “German Merck” and “Merck Darmstadt”, was founded in Darmstadt, Germany, in 1668, making it the world's oldest operating chemical and pharmaceutical company. The company was privately owned until going public in 1995. However, the Merck family still controls a majority (≈70%) of the company's shares. Following World War I, Merck lost possession of its foreign sites, including the Merck & Co. subsidiary in the United States. Merck & Co., which operates as Merck Sharp and Dohme (MSD) outside the U.S. and Canada, is now an independent company. Merck KGaA operates mainly in Europe, Africa, Asia, Oceania and Latin America. Since Merck & Co. holds the rights to the Merck name in the U.S. and Canada, the company operated under the umbrella brand EMD Chemicals in North America, and since 2010 as EMD Millipore (after the acquisition of Millipore Corporation), formed from the initials of Emanuel Merck, Darmstadt. Founded in 1668 in Darmstadt, Merck KGaA of Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The success of the export business to the United States led in 1887 to the establishment of an office in New York, which gave rise to their subsidiary [Merck & Co.](http://www.crunchbase.com/organization/merck-co-inc) four years later. Owing to World War I, Merck & Co. was expropriated in 1917. The two companies have been separate every since. Merck KGaA Subsidiaries: - [Merck Consumer Healthcare](http://www.crunchbase.com/organization/merck-consumer-healthcare) - [Merck Performance Materials](http://www.crunchbase.com/organization/merck-performance-materials)

CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.

Altos Labs is a biotechnology company focused on cellular rejuvenation programming to restore cell health and resilience, with the goal of reversing disease to transform medicine. The company comprises a community of leading scientists, clinicians, and leaders from both academia and industry working together towards this common mission. Altos has operations in the San Francisco Bay Area and San Diego, and in Cambridge, UK, with significant collaborations in Japan.

Rubedo Life Sciences is a biopharmaceutical company that is developing a diverse portfolio of innovative therapies that are engineered to target cells that are responsible for chronic age-related diseases. Its proprietary ALEMBIC drug discovery platform has generated novel first-in-class small molecules designed to selectively target senescent cells, which are important in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic, and other chronic diseases. The Rubedo leadership team is made up of industry leaders and pioneers in chemistry, technology, and life sciences, with extensive experience in drug development and commercialization ranging from large pharma to biotech innovators.

Pan-Biome Pharmaceuticals is a preclinical biopharmaceutical company focused on longevity and living healthier longer. In preclinical studies our natural-product-based small molecules significantly extended lifespan, while also having inhibitory effects against C. difficile and Inflammatory Bowel Diseases (IBD).

SL BIGEN is a research and development business that aims to save patients' lives through bio-genetic engineering. SL BIGEN is working on two projects: I a first-in-class mesenchymal stem cell line engineered to express disease-specific therapeutic genes, and (ii) a multi-engineered natural killer cell line expressing fourth generation chimeric antigen receptors. Cancer and neurological illnesses are among the therapeutic areas covered by the company.

Operator of an innovative anti-aging biotechnology company intended to target aging pathways for the next generation of personalized medicine in cancer and aging. The company focuses on the mTOR signal transduction pathway with the recent development of rapamycin analogs everolimus and temsirolimus targeting cell proliferation and FDA approval for metastatic breast cancer, and targeted therapies in this pathway for age-related diseases such as cancer and neurodegenerative diseases.

Shift Bioscience is using simulation guided cell rejuvenation to defeat the diseases of aging. Cellular reprogramming with Yamanaka factors can reverse aging in the dish but is not yet safe for clinical use. Shift has pioneered the first high-throughput, high-accuracy aging biomarker, which has been leveraged inside AI-based cell simulations to identify safer rejuvenation gene-factors. Shift envisions the development of a single drug-family that can treat multiple diseases of aging, after which full and continued health into old age becomes accessible by simple prescription.

Rejuveron Life Sciences AG is a fully integrated biotechnology platform company that invests in people and ideas to develop therapies and technologies to improve healthy aging and prolong lifespan.

Unity Biotechnology designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells; and designs senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected.

Senisca is a biotech start-up. They propose to create a new generation of oligonucleotide-based interventions to rewind the clock in old cells and target diseases and cosmetic signs of aging. They provide molecular and cellular biology and have patent-protected an innovation for the reversal of cellular senescence.

Developer of gene editing drugs designed to meet unmet medical needs. The company focuses on the research and development of innovative gene editing drugs and is rapidly advancing in vivo gene editing tools and related delivery systems, providing clients with curative gene editing-based solutions for genetic diseases.

New Limits specializes in advertising services, focusing on innovative strategies to enhance brand visibility and engagement. With a team of 5 professionals, the company leverages digital platforms and creative solutions to help businesses reach their target audience effectively. Since its establishment in 2017, New Limits has been committed to delivering tailored advertising campaigns that meet the unique needs of each client. The company's approach includes a mix of digital marketing techniques and content creation, aimed at driving performance and achieving measurable results for clients across various industries.

reverSASP Therapeutics creates innovative new drugs for aging-related diseases targeting senescent cells. With its deep understanding of underlining biology of aging-related diseases, it focuses on Senescence-associated secretory phenotype, or SASP, as a drug target.

Turn.bio is a biotechnology company developing drugs to reverse aging and age-related diseases. Utilizing a patented mRNA platform technology, ERA, the company is combating the effects of aging on the epigenome. The company’s proprietary mRNA platform technology, ERA and eTurna, a delivery platform specifically designed to enable nucleic acid therapeutics, combats the effects of aging in the epigenome, thus restoring optimal gene expression. It focuses on developing tailored therapies targeting indications in immune-related diseases like cancer and dermatological conditions, as well as therapies for ophthalmology, osteoarthritis, and the muscular system.

Starkage Therapeutics is a discovery-stage biotechnology company. They also provide treatment for idiopathic pulmonary fibrosis, neurodegenerative diseases, and metabolic dysfunction or hepatic fibroses.

Seneque works to find new biochemical pathways that deliver solutions and real progress. Their clinical research approach to supporting new technologies can increase lifespan by twenty percent. They are conducting a clinical research program evaluating the effects of nicotinamide mononucleotide and other synergistic molecules in humans.

Rubedo Life Sciences is a biopharmaceutical company that is developing a diverse portfolio of innovative therapies that are engineered to target cells that are responsible for chronic age-related diseases. Its proprietary ALEMBIC drug discovery platform has generated novel first-in-class small molecules designed to selectively target senescent cells, which are important in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic, and other chronic diseases. The Rubedo leadership team is made up of industry leaders and pioneers in chemistry, technology, and life sciences, with extensive experience in drug development and commercialization ranging from large pharma to biotech innovators.

Operator of a biotechnology firm intended to develop drugs that are dedicated to redefining and optimizing brain health and performance. The company develops novel nutritional and therapeutics products that are designed to support the brain's natural repair mechanisms to combat the effects of age-related cognitive decline, enabling people suffering from cognitive disorders to combat dementia, support brain health and improve cognitive performance.

We are a website and mobile app development shop based near Salt Lake City, Utah. We specialize in building websites with Webflow, the best website building tool in our opinion. We also specialize in iOS mobile apps built with Swift, but are expanding our horizons and using Flutter to create iOS and Android apps at the same time.

MPC Therapeutics is a biotechnology company. For patients with cancer and degenerative disorders, the company is presently concentrating on creating life-altering medications. They develop a class of compounds with the ability to modify mitochondrial processes in order to alter the conductivity of the cell and prevent the growth of diseases by using their medicinal chemistry and mitochondrial biology.